Efficacy and visual prognostic factors of intravitreal bevacizumab as needed for macular edema secondary to central retinal vein occlusion.
Efficacy and visual prognostic factors of intravitreal bevacizumab as needed for macular edema secondary to central retinal vein occlusion.
复制标题
DOI：
10.2147/opth.s74888
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Nakamura M
中科院分区：
文献类型：
--
作者：
Hirose M;Matsumiya W;Honda S;Nakamura M
我们的目的是研究眼内注射贝伐单抗治疗视网膜中央静脉阻塞（CRVO）继发黄斑水肿的疗效和预后因素。这是一项回顾性研究，包括27例连续患者的28只眼，这些患者患有CRVO所致黄斑水肿，并随访至少6个月。患者的平均年龄为66.3岁。患者在初次访视时接受玻璃体内注射贝伐珠单抗（1.25 mg）。当黄斑水肿持续或恶化时进行再治疗（按需方案）。主要结果测量是最佳矫正视力（BCVA）的平均变化。中心视网膜厚度（CRT）的变化作为次要结果进行评价。最后，确定了预测BCVA结果的有用因素。在6个月期间，平均注射次数为1.8次。平均BCVA（最小分辨角的对数）在初次注射后1个月（-0.097）、3个月（-0.14）和6个月（-0.25）时显著改善（分别为P <0.05、P <0.01和P <0.001）。平均CRT在1个月（− 250.4）、3个月（− 150.0）和6个月（− 187.2）时也有显著改善（P <0.001）。早期治疗和初始治疗后1个月BCVA改善更好是与6个月时视力结局更好显著相关的预后因素（P分别为0.047和0.029）。视需要玻璃体内注射贝伐单抗显著改善CRVO患者的视力和黄斑水肿。治疗前的时间和治疗的早期反应是影响视力结果的重要因素。
Our aim was to investigate the efficacy and prognostic factors of intraocular injections of bevacizumab as needed in patients with macular edema secondary to central retinal vein occlusion (CRVO). This is a retrospective study including 28 eyes of 27 consecutive patients with macular edema due to CRVO and followed for at least 6 months. The mean age of the patients was 66.3 years. The patients underwent an intravitreal injection of bevacizumab (1.25 mg) at the initial visit. Retreatments were performed when macular edema was persistent or worsened (as-needed regimen). The primary outcome measure was the mean change in best-corrected visual acuity (BCVA). The change in central retinal thickness (CRT) was evaluated as the secondary outcome. Finally, the factors useful for predicting BCVA outcome were determined. The mean number of injections was 1.8 over a period of 6 months. The mean BCVA (logarithm of minimum angle of resolution) was significantly improved at 1 (−0.097), 3 (−0.14), and 6 months (−0.25) after the initial injection (P<0.05, <0.01, and <0.001, respectively). The mean CRT was also improved significantly at 1 (−250.4), 3 (−150.0), and 6 months (−187.2) (P<0.001 each). Earlier treatment and better improvement in BCVA at 1 month after the initial treatment were the prognostic factors significantly associated with better visual outcomes at 6 months (P=0.047 and 0.029, respectively). Intravitreal injection of bevacizumab as needed significantly improved visual acuity and macular edema in CRVO patients. Time before the treatment and early response to the treatment were important factors for the visual outcome.